GlobeNewsWire
10 Nov 2025, 21:05 UTC · 44w ago
Verdict
Headline takes no side. We score TERN +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
TERN-701 demonstrated unprecedented Phase 1 Major Molecular Response (MMR) achievement rates in CML patients.
So whatPositive clinical efficacy data for a lead asset is the primary driver of valuation for clinical-stage biotech companies.
More positive than 98% of claims this week
Terns Pharmaceuticals has discontinued internal clinical development of its metabolic programs (including GLP1-RA and THR-β assets) to seek external partnerships.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 76% of claims this week
The company holds $295.6 million in cash and marketable securities, providing a financial runway into 2028.
So whatStrong cash runway reduces the immediate risk of dilutive equity financing, providing stability for investors.
More positive than 64% of claims this week
The company reported a net loss of $24.6 million for the third quarter of 2025.
More negative than 63% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
The company reported unprecedented Phase 1 efficacy data for TERN-701 and has a cash runway extending into 2028.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
1d ago
+176.9%
Price agrees with the score
$52.95 vs $19.12 close before publication (Nov 10) · not market-adjusted
TERN chart →
